STOCK TITAN

NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

New Enterprise Associates 17 and affiliates filed Amendment No. 3 to their Schedule 13D on Monte Rosa Therapeutics. They report beneficial ownership of 7,692,298 shares of common stock, representing 9.6% of the company based on 80,015,667 shares outstanding as of March 2, 2026.

The amendment states their ownership percentage has fallen by more than 1% solely because the number of Monte Rosa shares outstanding increased, and that no reporting person has traded in the last 60 days. NEA 17 holds the shares for investment purposes and the group outlines no current plans to change control, influence major corporate actions, or alter the issuer’s capital structure. Ali Behbahani also holds options to purchase 104,732 shares, bringing his calculated beneficial stake to 7,797,030 shares, or 9.7%.

Positive

  • None.

Negative

  • None.





61225M102

(CUSIP Number)
Stephanie Brecher
New Enterprise Associates, 1954 Greenspring Drive, Suite 600
Timonium, MD, 21093
(410)842-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
03/17/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 17, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
NEA Partners 17, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
NEA 17 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:03/19/2026
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:03/19/2026
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:03/19/2026
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:03/19/2026
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
Date:03/19/2026
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:03/19/2026
Edward T. Mathers
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Edward T. Mathers
Date:03/19/2026
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:03/19/2026
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:03/19/2026
Rick Yang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Rick Yang
Date:03/19/2026
Comments accompanying signature:
This Amendment No. 3 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

What stake does NEA 17 report in Monte Rosa Therapeutics (GLUE)?

NEA 17 and related reporting persons report beneficial ownership of 7,692,298 shares of Monte Rosa Therapeutics common stock. This represents 9.6% of the company, based on 80,015,667 shares outstanding as of March 2, 2026, per the issuer’s Form 10-K.

Why did NEA 17’s reported ownership percentage in GLUE decrease in this amendment?

The group’s reported ownership percentage decreased by more than 1% because Monte Rosa’s total shares outstanding increased. The amendment specifies that the change in percentage results from a higher share count, not from sales or other transactions by the reporting persons.

Did NEA 17 or its affiliates trade Monte Rosa (GLUE) shares in the last 60 days?

No. The filing explicitly states that none of the reporting persons has effected any transaction in Monte Rosa common stock in the last 60 days. The updated ownership percentages therefore reflect capital changes at the issuer, not recent market activity by NEA entities or managers.

What is Ali Behbahani’s individual beneficial ownership in Monte Rosa (GLUE)?

As of March 19, 2026, Ali Behbahani is the record owner of options to purchase 104,732 shares of Monte Rosa common stock exercisable within 60 days. Including these option shares, his aggregate beneficial ownership is reported as 7,797,030 shares, or 9.7% of the class.

Does NEA 17 indicate any plans to change control or strategy at Monte Rosa Therapeutics?

No. The filing states NEA 17 acquired its shares for investment purposes and lists no present plans for mergers, asset sales, board changes, capital structure changes, or other control-related actions at Monte Rosa, beyond the possibility of buying or selling shares based on future evaluations.

How is the 9.6% GLUE ownership figure in the NEA 17 filing calculated?

The reported 9.6% ownership is calculated using 80,015,667 shares of Monte Rosa common stock outstanding as of March 2, 2026. That share count comes from Monte Rosa’s Form 10-K, and the percentage reflects NEA 17’s 7,692,298 beneficially owned shares relative to that total.
Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

View GLUE Stock Overview

GLUE Rankings

GLUE Latest News

GLUE Latest SEC Filings

GLUE Stock Data

1.25B
72.21M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
BOSTON